Anti-tumor activity of fenretinide complexed with human serum albumin in lung cancer xenograft mouse model
Metrics: PDF 1348 views | HTML 1930 views | ?
Sandra Durante1,*, Isabella Orienti2,*, Gabriella Teti1, Viviana Salvatore1, Stefano Focaroli1, Anna Tesei3 , Sara Pignatta3 and Mirella Falconi1
1 DIBINEM—Department of Biomedical and Neuromotor Sciences, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy
2 FaBiT–Department of Pharmacy and Biotechnology, University of Bologna, Via San Donato 19, 240127, Bologna, Italy
3 Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori(IRST) IRCCS, Biosciences Laboratory, via P. Maroncelli 40, 47014, Meldola, FC, Italy
* These authors contributed equally to this work
Mirella Falconi, email:
Received: May 7, 2014 Accepted: May 28, 2014 Published: May 28, 2014
Sufficient knowledge regarding cellular and molecular basis of lung cancer progression and metastasis would help in the development of novel and effective strategies for the treatment of lung cancer. 4HPR is a synthetic retinoid with potential anti-tumor activity but is still limited because of its poor bioavailability. The use of albumin as a complexing agent for a hydrophobic drug is expected to improve the water solubility and consequently their bioavailability.This study investigated the antitumor activity of a novel complex between albumin and 4-HPR in a mouse model of human lung cancer and focuses on role and mechanism of Cav-1 mainly involved in regulating cancer and Acsvl3 mainly connected with tumor growth.
Their expressions were assayed by immunohistochemistry and qRT-PCR, to demonstrate the reduction of the tumor growth following the drug treatment. Our results showed a high antitumor activity of 4HPR-HSA by reduction of the volume of tumor mass and the presence of a high level of apoptotic cell by TUNEL assay. The downregulation of Cav-1 and Acsvl3 suggested a reduction of tumor growth.
In conclusion, we demonstrated the great potential of 4HPR-HSA in the treatment of lung cancer. More data about the mechanism of drug delivery the 4HPR-HSA are necessary.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.